New study led by Horizon and supported by Roche Canada delivers cancer treatment in the comfort of a patient's home
MISSISSAUGA, ON, May 28, 2025 /CNW/ - For the first time in Canada, a patient has received cancer immunotherapy by subcutaneous (under the skin) injection in their home, thanks to an innovative research initiative by Horizon Health Network (Horizon), in collaboration with Roche Canada, the New Brunswick Extra-Mural Program, and ResearchNB, and with support from Vitalité Health Network.
The project originated with a research study led by Horizon medical oncologists Dr. Mahmoud Abdelsalam, Dr. Luisa Galvis and Dr. James Michael whereby New Brunswick patients diagnosed with certain types of lung cancer receive Health Canada-authorized subcutaneous cancer immunotherapy at home, administered by nurses from Medavie's New Brunswick Extra-Mural Program. The initiative was formally announced by the New Brunswick delegation during the annual BIO International Convention in June 2024 in San Diego, California, and the first treatment milestone occurred in New Brunswick this past March.
'This trial marks a turning point in lung cancer care—bringing treatment from the hospital to patients' homes, where they are most comfortable,' said Dr. Abdelsalam, who served as principal investigator of the research initiative. 'We are proud to lead this Canadian-first trial from New Brunswick, showing that innovation in health care can start right here at home, improving the quality of care for New Brunswickers.'
The study was initially designed to bring care closer to communities. However, Dr. Abdelsalam challenged the team to go further — to 'close the last mile' by delivering modern cancer therapies directly to patients' homes.
Previously, patients travelled to hospital-based infusion centres for intravenous cancer treatments, often spending at least 30 to 60 minutes per visit. The new subcutaneous injection reduces treatment time to about seven minutes, offering a more convenient, less invasive option that minimizes disruptions to patients' daily life, reduces the strain on health care providers, and increases capacity in the health care system.
'The reality is, if patients must leave their communities, take time off work, arrange childcare or organize transportation, it disrupts their lives significantly,' said Jennifer Sheils, Horizon's Vice-President of Strategy, Transformation and Chief Innovation Officer. 'They occupy IV therapy hospital chairs, require nursing and pharmacy resources and often face the challenge of travelling home while feeling unwell. These impacts extend beyond the treatment day and can affect their overall well-being and financial stability.'
As industry partners like Roche Canada introduce new therapies that move beyond traditional IV delivery, Horizon is leading the way in rethinking cancer care by putting patient needs first and helping to build a more efficient, responsive health care system.
Key benefits of an injection (subcutaneous) formulation to the patient, compared to traditional IV formulations, can include:
'The challenges faced by healthcare systems in Canada have never been greater. Horizon Health's outstanding leadership shows that transforming this system is possible. By thinking differently about how we collaborate, we can deliver better care to patients and their families. We are very proud to partner with Horizon Health on this project, which will help ensure all patients have access to the best innovation in healthcare, when they need it - a key part of Roche's vision,' said Dr. Dan Edgcumbe, Vice President of Medical and Regulatory Affairs at Roche Pharma Canada. 'This experience will help us all better understand the full value of healthcare innovation to provide more accessible, flexible care options while expanding healthcare system capacity.'
Through this partnership, patients now have the choice to receive injections at home, reducing disruption to their daily lives and alleviating pressures on hospital resources. This innovative model empowers patients while supporting a more efficient and patient-centered health care system.
This approach is also expected to improve health system operations by reducing pressure on infusion clinics, increasing treatment capacity, optimizing workflow and potentially lowering overall costs per patient.
Horizon hopes health care systems across Canada will look to this example as a model for accelerating patient-centred innovation. Advancing research and adopting new approaches to care delivery will be critical to building a more sustainable health care system.
Horizon is committed to fostering a culture of improving patient outcomes through research and innovation initiatives like this one. Each year, Horizon Research Services supports approximately 117 clinical trials for new treatments and solutions, along with nearly 307 investigator-led studies advancing health care knowledge and practice.
Patients interested in participating in this study, referred to as Subcutaneous Treatment with Immunotherapy for Cancer Patients at Home, or STITCH-01, or another Horizon research study are encouraged to complete a research application form, available on the Horizon website.
About Horizon Health Network
Horizon Health Network is the largest regional health authority – and one of the largest employers – in New Brunswick, and the second-largest health authority in Atlantic Canada. Our leadership and health care providers are experts in diverse areas of health and community services and provide services to a half a million people. The organization has an annual budget of approximately $1.4 billion and has more than 14,000 employees, 1,242 physicians and 1,300 volunteers, as well as 17 foundations and 16 auxiliaries and alumnae organizations.
About Roche Canada
At Roche Canada, patients and science are at the heart of everything we do. Our passion for science and our commitment to relentlessly pursuing the impossible for patients have made us one of the world's leading pharmaceutical, in-vitro diagnostics, and diabetes care management companies.
With our combined strength in diagnostics and pharmaceuticals, we're driving healthcare forward, while ensuring we deliver meaningful benefits for patients and sustainable healthcare systems. We are committed to creating a world where we all have more time with the people we love.
And we're adding our expertise in new areas, such as artificial intelligence, real world data collection and analysis and collaborating with many different sectors and industries.
Having the courage to reinvent ourselves and question the status quo is what patients and healthcare systems expect from Roche - and our commitment is as strong today as it was on the first day of our Canadian journey in 1931. Today, Roche Canada employs nearly 2,000 people at its offices in Mississauga, Ontario, in Laval, Quebec, and across the country from coast to coast to coast.
For more information, please visit www.RocheCanada.com or follow Roche Canada on LinkedIn.
About ResearchNB
ResearchNB is the province's research and innovation enabler. With offices in Fredericton, Saint John and Moncton, it provides New Brunswick's research sector with critical leadership and support including advocacy, initial funding, connections to potential partners, and the translation of science into economic opportunities. Projects developed in partnership with ResearchNB help New Brunswickers to thrive through research that leads to new, innovative business practices and products.
About New Brunswick Extra-Mural Program
The New Brunswick Extra-Mural Program (EMP) delivers primary health care services to New Brunswickers of all ages in their homes and communities. EMP, known by many as the 'hospital without walls', includes a team of over 850 professionals who provide quality home health care services to eligible residents when their needs can be met safely in the community. EMP operates on a client and family centered model with a focus on building and maintaining partnerships with clients and their families, physicians, agencies, departments and other service providers to best meet patient needs.
SOURCE Hoffmann-La Roche Limited (Roche Canada)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNET
2 hours ago
- CNET
AT&T Has a New Affordable Senior Mobile Plan -- and Sorry, 55 Counts as a 'Senior'
AT&T has revealed its new phone plan for seniors, which offers mobile service at a discount for customers 55 years old and up. (Yes, Gen X, that's you -- or some of you, at least.) While the new plan only has the essentials, it's also cheaper than the carrier's feature-packed options. Even better, it's notably more affordable than AT&T's former senior plan. Carriers typically offer several plans to satisfy a range of customers, from the frugal to those that are willing to pay for every perk and bundled streaming service they can get. But plans targeting older Americans are often more bare-bones offerings, offered at lower prices to appeal to customers on fixed and limited incomes. AT&T's new AT&T 55 Plus plan is the most affordable it's offered in years. In exchange, the AT&T 55 Plus plan is pretty basic. For $40 per month for a single line (or $35 per month per line with two lines), you'll get unlimited voice calls, texting and data in the US, Canada and Mexico, and though AT&T's senior plan page indicates it has "5G access included," there's no clarity on which circumstances will enable high-speed data downloads and uploads on the senior plan. The plan also has 10GB of hotspot data per line per month, which is more generous than some other carrier offerings on our best senior plans list, along with a maximum 720p (SD) streaming speed for video. The plan also provides access to AT&T's free ActiveArmor app that blocks spam calls. Previously, AT&T offered a slightly discounted senior phone plan at $62 per month that was only available to customers living in Florida. Verizon retains a similar Florida-only senior plan. T-Mobile has several plans for seniors, from an older and basic Essentials Choice 55 plan starting at $45 per month up to Experience Beyond w/ 55 Plus starting at $85 per month and offering all the perks and extras of T-Mobile's other plans, including a five-year plan price guarantee, streaming services and satellite service beyond T-Mobile's network. Here's a breakdown of the best senior plans carriers offer 55-years-old and up customers: Best Senior Plans: T-Mobile, AT&T, Mint Mobile and Verizon Plan Cost 1 line (AutoPay) Cost 4 lines (AutoPay) High-speed data Hotspot data limit Price guarantee Max number of lines Streaming resolution T-Mobile Essentials Choice 55 $45 N/A 50GB Unlimited 3G N/A 2 480p (SD) T-Mobile Go5G 55 Plus $75 N/A Unlimited 5G 50GB N/A 2 Up to 4K T-Mobile Experience Beyond w/ 55+ $85 N/A Unlimited 5G 250GB 5 years 2 Up to 4K AT&T AT&T 55+ $40 $140 Unlimited 10GB N/A 10 480p (SD) Mint Mobile Mint 55 $15 N/A 5GB Shared 5GB main data budget N/A 5 480p (SD) Verizon Verizon 55 Plus $62 N/A Unlimited 4G LTE Unlimited 3G N/A 2 480p (SD) It's worth noting that every carrier plan's listed lowest price requires customers to sign up for autopay -- otherwise, the plans are more expensive every month. Customers must also prove their age by submitting an identification document to their carrier. Later this summer, AT&T will also offer a bundle combining two lines of AT&T 55+ with the customer's choice of either AT&T Fiber or AT&T Internet Air fixed wireless access internet, according to the carrier's blog post.
Associated Press
3 hours ago
- Associated Press
Electric Metals Announces Termination of Agreement With Terrella Capital
TORONTO, ON / ACCESS Newswire / June 6, 2025 / Electric Metals (USA) Limited ('EML' or the 'Company') (TSXV:EML)(OTCQB:EMUSF) announces that the Company and Terrella Capital Ltd. ('Terrella') have mutually agreed to terminate their business consulting services agreement, originally announced on April 15, 2025. The agreement was formally terminated effective May 27, 2025. In connection with the termination, the 250,000 stock options previously contemplated for grant to Terrella under the agreement have been cancelled and will not be issued. About Electric Metals (USA) Limited Electric Metals (USA) Limited (TSXV: EML) (OTCQB: EMUSF) is a US-based mineral development company with manganese and silver projects geared to supporting the transition to clean energy. The Company's principal asset is the Emily Manganese Project in Minnesota, the highest-grade manganese deposit in North America, which has been the subject of considerable technical studies, including National Instrument 43-101 Technical Reports - Resource Estimates. The Company's mission in Minnesota is to become a domestic US producer of high-value, high-purity manganese metal and chemical products to supply the North American electric vehicle battery, technology and industrial markets. With manganese playing a critical and prominent role in lithium-ion battery formulations, and with no current domestic supply or active mines for manganese in North America, the development of the Emily Manganese Project represents a significant opportunity for America, the State of Minnesota and for the Company's shareholders. For further information, please contact: Electric Metals (USA) Limited Brian Savage CEO & Director (303) 656-9197 or Valerie Kimball Director Investor Relations 720-933-1150 [email protected] Forward-Looking Information This news release contains 'forward-looking information' and 'forward-looking statements' (collectively, 'forward-looking information') within the meaning of applicable securities laws. Forward-looking information is generally identifiable by use of the words 'believes,' 'may,' 'plans,' 'will,' 'anticipates,' 'intends,' 'could', 'estimates', 'expects', 'forecasts', 'projects' and similar expressions, and the negative of such expressions. Such statements in this news release include, without limitation: the ability of the Company to complete the Offering; the size, terms and timing of the Offering; participation in the Offering by insiders of the Company; the timing and receipt of TSXV and other approvals required in connection with the Offering; the intended use of proceeds of the Offering; the Company's mission to become a domestic US producer of high-value, high-purity manganese metal and chemical products to supply the North American electric vehicle battery, technology and industrial markets; that manganese will continue to play a critical and prominent role in lithium-ion battery formulations; that with no current domestic supply or active mines for manganese in North America, the development of the Emily Manganese Project represents a significant opportunity for America, Minnesota and for the Company's shareholders; and planned or potential developments in ongoing work by Electric Metals. These statements address future events and conditions and so involve inherent risks, uncertainties and other factors that could cause actual events or results to differ materially from estimated or anticipated events or results implied or expressed in such forward-looking statements. Such risks include, but are not limited to, the failure to obtain all necessary stock exchange and regulatory approvals; investor interest in participating in the Offering; and risks related to the exploration and other plans of the Company. Forward-looking information is based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and perception of trends, updated conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances at the date such statements are made. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events, or developments, except as required by law. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE: Electric Metals (USA) Limited press release
Associated Press
3 hours ago
- Associated Press
Battery X Metals Successfully Validates Next-Generation Battery Rebalancing Machine on Light-Duty Electric Vehicle Model that Exhibited Significant Real-World Cell-Imbalance-Related Capacity Degradation, Achieving 100% Imbalance Recovery and 38% of Rated Capacity Restored in Preliminary Trial
News Release Highlights: X Rebalancing Technologies successfully validates its next-generation battery rebalancing machine on a commercial electric truck battery that had experienced significant real-world imbalance, expanding functionality to include a Class 3 light-duty EV model. 2.0 achieved 100% recovery of imbalance-related capacity loss and a 37.7% increase of the rated capacity, underscoring the machine's effectiveness on a significantly imbalanced battery pack. trial conducted on a significantly imbalanced battery pack provided by an authorized Canadian distributor of the electric truck, highlighting market interest and broader demand for cost-effective solutions to restore electric vehicle battery capacity and avoid costly full-pack replacements. VANCOUVER, BC / ACCESS Newswire / June 6, 2025 / Battery X Metals Inc. (CSE:BATX)(OTCQB:BATXF)(FSE:5YW, WKN:A40X9W)('Battery X Metals' or the 'Company') an energy transition resource exploration and technology company, announces that further to its news releases dated May 9, 2025, May 23, 2025, and May 30, 2025, its wholly-owned subsidiary, Battery X Rebalancing Technologies Inc. ('Battery X Rebalancing Technologies'), has expanded the functionality of its next-generation lithium-ion battery rebalancing hardware and software platform to include a fully electric, Class 3 commercial electric vehicle, or light-duty electric vehicle (the 'Electric Truck'), and has achieved successful preliminary trial results (the 'Trial') on an 144-battery cell Electric Truck battery pack which had exhibited significant natural imbalance caused by real-world conditions, demonstrating 100% recovery of a naturally occurring imbalance-related capacity loss, and a 37.7% increase of the Rated Capacity (as defined herein) of the Electric Truck's battery pack, composed of lithium nickel manganese cobalt oxide (NMC) materials (the 'Electric Truck Battery Pack'). The Trial results (the 'Results') were performed using Battery X Rebalancing Technologies' second-generation, patent-pending battery rebalancing machine ('Prototype 2.0") on the Electric Truck Battery Pack. The Electric Truck Battery Pack has been assessed to have a rated full capacity of 176 ampere-hours (Ah) (the 'Rated Capacity'), as specified on the nameplate affixed to the Electric Truck Battery Pack. Initially, the Electric Truck Battery Pack was fully charged using a J1772 (Type 1) AC charging port, delivering 40 amperes (A) of current. This Level 2 AC charging step, consistent with North American EV standards¹, was managed by the vehicle's onboard systems. Once the dashboard displayed a 100 percent state of charge and the charger application indicated the vehicle was no longer requesting current, Prototype 2.0 initiated its patent-pending battery rebalancing process. A rebalancing current between 0 and 3 amperes was then individually applied to each of the battery cells, charging them simultaneously to a target voltage of 4.20 volts (the 'Voltage Target'). The Voltage Target falls within the standard operating range for NMC lithium-ion cells (3.0V to 4.20V), with 4.20V commonly recognized as full capacity in the industry². The Results show that 66.3 Ah of capacity, previously lost due to battery-cell imbalance, was successfully restored on the Electric Truck Battery Pack. This represents approximately 37.7 percent of the Rated Capacity of the unbalanced Electric Truck Battery Pack. The restored capacity corresponds to the full theoretical rebalancing potential based on achieving the Voltage Target across all cells and reflects complete recovery of the significant imbalance identified. These results were validated using Prototype 2.0's integrated software feature, which measures ampere-hour capacity restored through rebalancing on a per-cell basis. The software also identified the maximum individual cell discrepancy to be 66.3 Ah, relative to the Rated Capacity. Battery X Rebalancing Technologies interprets these Results as confirmation of Prototype 2.0's ability to recover significant imbalance-induced battery-cell capacity loss through precise voltage alignment and active cell-level rebalancing. The expanded functionality development for the Electric Truck builds on a series of prior advancements by Battery X Rebalancing Technologies, as disclosed in the Company's news release dated May 9, 2025, which announced that Battery X Rebalancing Technologies had entered into a non-commercial, collaborative scope of services agreement (the 'Factor E Agreement') with Factor E Motors Ltd., a Vancouver-based automotive service centre specializing in out-of-warranty Tesla vehicles. The Factor E Agreement is intended to support the continued development of Prototype 2.0, with an initial focus on Tesla Model 3 and Model X battery packs currently held by Factor E Motors. This progress was further advanced, as disclosed the Company's news releases dated May 23, 2025, and May 30, 2025, which announced the expansion of Prototype 2.0's development to include Nissan Leaf battery packs and confirmed the successful rebalancing of a naturally imbalanced Nissan Leaf battery pack. This achievement marked a key milestone in validating Prototype 2.0's compatibility with the #2 most common out-of-warranty electric vehicle model in the United States. Together, these initiatives underscore Battery X Rebalancing Technologies' commitment to demonstrating the adaptability of its technology across multiple real-world electric vehicle platforms and highlight the increasing demand for practical, cost-effective battery reconditioning solutions. Results Significance of Results & Market Opportunity for the Electric Truck The Results of the Trial demonstrate that Prototype 2.0 is capable of effectively rebalancing lithium-ion battery packs exhibiting significant, naturally occurring battery cell imbalance. This successful outcome builds upon prior validation of Battery X Rebalancing Technologies' patent-pending rebalancing technology, including independent validation by the National Research Council of Canada (as detailed below), and the Company's previously disclosed news release dated May 30, 2025 announcing successful rebalancing of naturally imbalanced Nissan Leaf battery pack, the #2 most common out-of-warranty electric vehicle model in the United States. Importantly, the Results not only confirm the technical functionality of Prototype 2.0 in a real-world electric vehicle platform, but also highlight its potential to restore substantial lost capacity-an outcome that supports the growing demand for practical, cost-effective battery recovery solutions. The Electric Truck Trial reinforces the relevance of Battery X Rebalancing Technologies' patent-pending Prototype 2.0 in real-world environments and signals a broader opportunity to extend the useful lifespan of aging electric vehicle battery packs. The Electric Truck and Electric Truck Battery Pack were provided at no cost to Battery X Rebalancing Technologies for testing and validation by an authorized Canadian distributor of the Electric Truck (the 'Distributor'), who advised that it owns a fleet of approximately 20 Electric Trucks (the 'Electric TruckFleet'). Several vehicles within this fleet have reportedly experienced significant capacity degradation due to battery cell imbalance. The expanded functionality development and subsequent Trial were initiated in response to the Distributor's interest in identifying a viable alternative to full battery replacement, which it noted could be prohibitively expensive. The objective of the Trial was to assess whether Prototype 2.0 could successfully rebalance a battery pack from the Electric Truck Fleet. The positive Results are expected to inform ongoing discussions with the Distributor regarding the potential deployment of Prototype 2.0 across its broader fleet to restore and extend battery life while mitigating potentially costly battery replacements. Further, the Company has been advised by the Distributor that approximately 700 Electric Trucks are currently deployed across Canada, owned by a combination of the Electric Truck's parent company, authorized dealers, commercial fleet operators, and private fleet owners. According to the Distributor, many of these vehicles have encountered similar battery pack capacity degradation attributed to battery cell imbalance. This highlights a market opportunity for Battery X Rebalancing Technologies to provide a cost-effective rebalancing solution for electric vehicle owners seeking to avoid premature battery replacement. In parallel with these developments, Battery X Rebalancing Technologies is advancing the implementation of standardized operating procedures (SOPs) for rebalancing the Electric Truck Battery Pack, along with user interface and workflow optimizations for Prototype 2.0. Battery X Rebalancing Technologies is also progressing efforts to formalize a commercial manufacturing agreement to support scalable production and deployment capabilities. These initiatives are part of a broader commercialization strategy and are not limited to any single third-party opportunity, with the exception of the Electric Truck-specific SOPs, which are being developed in direct response to the potential opportunity identified through the Trial. There can be no assurance that Battery X Rebalancing Technologies will establish commercial arrangements with any third party at this time. While the Company is encouraged by the progress to date and the evident market need, any future commercial arrangement remains subject to further validation, negotiation, and operational readiness. The Problem: Rising EV Adoption Presents New Battery Lifecycle Challenges In 2024, global EV sales reached approximately 17.1 million units, representing a 25% increase from 20233. With cumulative global EV sales from 2015 to 2023 totaling an estimated over 40 million units4, a significant share of the global EV fleet is expected to exit warranty coverage over the coming years. By 2031, nearly 40 million electric, plug-in hybrid, and hybrid vehicles worldwide are anticipated to fall outside of their original warranty coverage5,6. This projection is based on current EV adoption figures and standard industry warranty terms, and underscores a growing risk for EV owners facing battery degradation, reduced capacity, and costly replacement requirements7. As the global EV fleet continues to expand, the demand for technologies that extend battery life, reduce long-term ownership costs, and support a sustainable transition to electric mobility is increasing. The Solution: Pioneering Next-Generation Technologies to Support Lithium-Ion Battery Longevity Battery X Rebalancing Technologies' proprietary software and hardware technology aims to address this challenge by extending the lifespan of EV batteries. This innovation is being developed with the aim to enhance the sustainability of electric transportation and the goal to provide EV owners with a more cost-effective, environmentally friendly ownership experience by reducing the need for costly battery replacements. Battery X Rebalancing Technologies' rebalancing technology, validated by the National Research Council of Canada ('NRC'), focuses on battery cell rebalancing. The NRC validation demonstrated the technology's ability to effectively correct cell imbalances in lithium-ion battery packs, recovering nearly all lost capacity due to cell imbalance. The validation was conducted on battery modules composed of fifteen 72Ah LiFePO₄ cells connected in series. The cells were initially balanced to a uniform state of charge (SOC), with a measured discharge capacity of 71.10Ah. In the validation test, three of the fifteen cells were then artificially imbalanced-one cell was charged to a 20% higher SOC, and two cells were discharged to a 20% lower SOC-resulting in a reduced discharge capacity of 46.24Ah, following rebalancing using Battery X Rebalancing Technologies' rebalancing technology. These advancements establish Battery X Rebalancing Technologies as a participant in lithium-ion and EV battery solutions, aiming to tackle the critical challenges of capacity degradation of battery packs and expensive replacements. By extending the lifecycle of battery materials within the supply chain, Battery X Rebalancing Technologies aims to support the energy transition and promote a more sustainable future. 1 EVESC, 2 Battery University,3 Rho Motion - Global EV Sales 2024, 4 IEA Global EV Outlook 2024, 5 IEA, 6 U.S. News, 7 Recurrent Auto About Battery X Metals Inc. Battery X Metals (CSE:BATX)(OTCQB:BATXF)(FSE:5YW, WKN:A40X9W) is an energy transition resource exploration and technology company committed to advancing domestic and critical battery metal resource exploration and developing next-generation proprietary technologies. Taking a diversified, 360° approach to the battery metals industry, the Company focuses on exploration, lifespan extension, and recycling of lithium-ion batteries and battery materials. For more information, visit On Behalf of the Board of Directors Massimo Bellini Bressi, Director For further information, please contact: Massimo Bellini Bressi Chief Executive Officer Email: [email protected] Tel: (604) 741-0444 Disclaimer for Forward-Looking Information This news release contains forward-looking statements within the meaning of applicable Canadian securities laws. Forward-looking statements in this release relate to, among other things: the continued development, testing, and optimization of Prototype 2.0; the expansion of its functionality to include additional electric vehicle platforms, including Class 3 light-duty commercial electric trucks; the Company's interpretation of preliminary trial results, including 100% imbalance-related capacity loss recovery and 37.7% increase of the Rated Capacity; the effectiveness of Prototype 2.0 in restoring lost capacity caused by battery cell imbalance; the relevance of the Trial in real-world operating conditions; the possibility of future commercial discussions with the Canadian distributor of the Electric Truck; the potential deployment of Prototype 2.0 across the distributor's Electric Truck Fleet; the estimated number of Electric Trucks deployed across Canada; the broader demand for rebalancing technologies to extend the useful life of electric vehicle battery packs; the scalability of Battery X Rebalancing Technologies' platform to meet market demand; the implementation of standardized operating procedures (SOPs) for Electric Truck rebalancing; user interface and workflow optimizations; and the progress toward formalizing a commercial manufacturing agreement to support scalable production and deployment capacity. These forward-looking statements reflect management's current expectations, estimates, projections, and assumptions as of the date of this news release. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, but are not limited to: the ability to complete further testing and validation of Prototype 2.0; variability in performance across different battery chemistries or EV platforms; the timing, structure, and outcome of any potential commercial discussions or agreements with distributors or other fleet operators; customer and market adoption; the ability to scale production through third-party manufacturing; successful implementation of SOPs and software enhancements; regulatory developments; operational and logistical challenges; and the ability to execute commercial contracts and generate revenue. There can be no assurance that Prototype 2.0 will achieve full commercialization, that any commercial agreements will be entered into, or that Battery X Metals Inc. or Battery X Rebalancing Technologies will generate revenue from the initiatives described herein. The realization of any commercial opportunity remains subject to further validation, negotiation, third-party readiness, and successful execution of definitive agreements. Battery X Metals Inc. undertakes no obligation to revise or update any forward-looking statements to reflect future events or circumstances, except as required by applicable law. Investors are encouraged to consult the Company's continuous disclosure filings available under its profile at for additional risk factors and information. SOURCE: Battery X Metals press release
